Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23848679 | 0.88 | — | — | |
| SCHEMBL24870544 | 0.88 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24599551 | 0.83 | — | — | |
| SCHEMBL24599546 | 0.83 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24870390 | 0.83 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23867804 | 0.83 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23867810 | 0.83 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24462730 | 0.83 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23867801 | 0.82 | BCL2 (0.31) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL25504163 | 0.78 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345701-B1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | TAS1R3 3356/4885TAS1R1 2848/4885TAS1R2 3400/4885 |
| US-11345701-B1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | TAS1R3 3356/4885TAS1R1 2848/4885TAS1R2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.